The properties of these cells, which don’t prompt an immune reaction, allow them to be used as an “off-the-shelf” treatment without accompanying immunosuppressants that put patients at greater risk for infection, among other side effects.Some patients with blood cancer are treated with a stem cell transplant, in which cells from a healthy donor are infused into their bloodstream with the intent that those cells will travel to the bone marrow and form new healthy blood cells. MesoBlast said investigators weren’t willing to enroll children in such a trial. Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. In March and April, Mesoblast conducted a small study at New York City's Mount Sinai Hospital to evaluate if its lead drug candidate, remestemcel-L, could …
You can reach her at sdecrescenzo@xconomy.com.
)“I do think that the two prior randomized trials convincingly show that the [earlier version of remestemcel], at least in the population that was being studied, which is similar but not the same, clearly did not have meaningful activity,” Hinrichs said.
Bank of New York Mellon Corp now owns 12,788 shares of the company's stock worth $145,000 after purchasing an additional 1,000 shares in the last quarter. Cases in California topped 600,000 as …
Mesoblast attracts the top in field—people who want to make a positive contribution to delivering a paradigm shift in … An FDA advisory committee Thursday voted 9-1 to recommend that the agency approve a stem cell therapy developed by MesoBlast as a treatment for acute graft-versus-host disease (aGVHD) in children.
Xconomy is a registered service mark of Xconomy, Inc.
Overall, 70 percent of the patients responded, including 76 percent of the 25 patients whose condition was graded as most severe. The Company’s portfolio of Phase 3 product candidates are: Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and biotechnology companies. Its decision on remestemcel is anticipated by September’s end. On day 100, 74 percent of patients remained alive; on day 180, 69 percent.However, the trial was neither randomized nor controlled, raising concerns of confounding factors and potential bias. Analyses of results from those earlier trials prompted MesoBlast’s decision to focus the drug’s further development to steroid-refractory pediatric patients.
Sarah de Crescenzo is an Xconomy editor based in San Diego. The panel weighed the need for a new way to address the potentially fatal condition against shortcomings of the clinical trial the Australian biotech conducted to evaluate the investigational cell therapy.The MesoBlast cell therapy, remestemcel-L (Ryoncil), is made from mesenchymal cells taken from healthy donors.
This team is responsible for the strategic direction, operations and success of our company.
(The committee recorded the tally as 8-2, but a MesoBlast representative said one “no” vote was made in error. Finally, Bank of New York Mellon Corp lifted its position in shares of Mesoblast by 8.5% during the second quarter.
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your researchAdvice for funding and future transformational opportunities© 2007-2020, Xconomy, Inc. Nine panelists felt the available data did indicate efficacy.
A U.S. trial of its remestemcel-L therapy to care for coronavirus patients is expected to be completed within three to four months. In its presentation to the advisory panel the company said the remestemcel manufacturing process has been improved since those trials in ways that have made the treatment more potent.The panel voted on whether MesoBlast provided enough clinical data to show that its therapy was effective in treating aGVHD in this narrower group. But the company said randomization and controlled design would be incorporated into a planned post-marketing study in adults.In previous clinical trials in wider patient populations, the treatment missed the primary goal.
Hedge funds and other institutional investors own 2.11% of the company's stock. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020, and if approved, Mesoblast will make RYONCIL immediately available in the United States.The Company also has a promising emerging pipeline and next generation technologies.Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. All rights reserved. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression. “So, you know, do we think that these tweaks to the manufacturing have suddenly made it highly effective, and the change in patient population has suddenly made it highly effective?”Jorge Garcia, division chief of solid tumor oncology at University Hospitals Seidman Cancer Center in Cleveland, however, said while it isn’t clear how the treatment compares to other drugs used to treat patients with the condition, the data indicate it is safe and has shown “some efficacy.”Although the FDA considers advisory panel recommendations during drug reviews, committee recommendations are not binding, and the agency doesn’t always follow them.